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Background: Psychotropic agents known to cause sedation are associated with an increased risk of falls, but the
role of psychiatric illness as an independent risk factor for falls is not clear. Thus, this study aimed to investigate the
association between psychiatric disorders, psychotropic medication use and falls risk.
Methods: This study examined data collected from 1062 women aged 20-93 yr (median 50 yr) participating in the
Geelong Osteoporosis Study, a large, ongoing, population-based study. Depressive and anxiety disorders for the
preceding 12-month period were ascertained by clinical interview. Current medication use and falls history were
self-reported. Participants were classified as fallers if they had fallen to the ground at least twice during the same
12-month period. Anthropometry, demographic, medical and lifestyle factors were determined. Logistic regression
was used to test the associations, after adjusting for potential confounders.
Results: Fifty-six women (5.3%) were classified as fallers. Those meeting criteria for depression within the past 12
months had a 2.4-fold increased odds of falling (unadjusted OR = 2.4, 95% CI 1.2-4.5). Adjustment for age and
mobility strengthened the relationship (adjusted OR = 2.7, 95% CI 1.4-5.2) between depression and falling, with
results remaining unchanged following further adjustment for psychotropic medication use (adjusted OR = 2.7,
95% CI 1.3-5.6). In contrast, past (prior to 12-month) depression were not associated with falls. No association was
observed between anxiety and falls risk. Falling was associated with psychotropic medication use (unadjusted OR = 2.8,
95% CI 1.5-5.2), as well as antidepressant (unadjusted OR = 2.4, 95% CI 1.2-4.8) and benzodiazepine use (unadjusted
OR = 3.4, 95% CI 1.6-7.3); associations remained unchanged following adjustment for potential confounders.
Conclusion: The likelihood of falls was increased among those with depression within the past 12 months,
independent of psychotropic medication use and other recognised confounders, suggesting an independent
effect of depression on falls risk. Psychotropic drug use was also confirmed as an independent risk factor for falls,
but anxiety disorders were not. Further research into the underlying mechanisms is warranted.
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Falls are common, with up to 30% of community dwelling
and 50% of institutionalized older adults falling every year
[1]. It has been reported that as many as 10% of falls result
in major injury often leading to institutionalization and
death. In Australia alone, there has been a four-fold in-
crease in the number of deaths resulting from falls since
2002; this is thought to be due to the aging population,
with women accounting for over half of deaths due to
falling [2].
Advanced age, mobility, sensory and medical factors,
cognitive capacity, certain medications, and environmen-
tal hazards are known risk factors for falls among older
adults [3]. Another possible risk factor for falls is depres-
sion. It has been shown to precede falls in the elderly,
and is also a possible outcome of falls, as with increased
anxiety, decreased satisfaction with life and activity
restriction [3,4]. Psychotropic medications also increase
risk of falls [5], possibly due to their sedative nature, and
thus are a potential mediator of the relationship between
psychiatric disorders and falls. However, the exact under-
lying mechanism(s) of action for the relationship between
psychiatric disorders and falls remains unclear. Moreover,
it is uncertain whether the relationship occurs among
younger adults or those residing within the community,
rather than in institutions.
As such, we aimed to investigate the association be-
tween depressive and anxiety disorders, psychotropic
medication use, and falls in a large, randomly-selected,
population-based sample of women spanning the full
adult age-spectrum. We also aimed to examine the role
of potential confounders in accounting for any observed
associations.
Methods
Participants
Data were derived from an age-stratified, population-
based sample of women enrolled in the Geelong Osteo-
porosis Study (GOS). Originally, 1,494 women (aged
20–94 yr, response 77.1%) were randomly recruited
from the electoral rolls for the Barwon Statistical Division
(south-eastern Australia) between 1994 and 1997 and have
returned for ongoing assessment [6]. Between 2004 and
2008, 881 of the original sample returned for a 10-year
follow-up assessment (participation 82.1%) and an add-
itional sample of 246 women aged 20–29 years was
recruited (participation 70.9%), allowing for continuing in-
vestigation of the full adult age range [7]. Of the 1127
women who participated in the GOS during 2004–2008,
participants for whom psychiatric data were not available
for this phase (n = 32), did not return their questionnaire
(n = 10), were unable to recall year of last psychiatric
episode (n = 2), and were current users of anticonvulsant
(n = 13) and antipsychotic medications (n = 8), wereexcluded, resulting in a sample of 1062 women aged
20-93 yr eligible for this analysis. All participants gave
written, informed consent, and the study was approved by
the Human Research Ethics Committee at Barwon Health.
Measurements
Outcome variable
The number of falls occurring during the 12-months
prior to the study assessment (2004–2008) was docu-
mented by self-report questionnaire. The definition
“when you suddenly find yourself on the ground, with-
out intending to get there, after you were in either a
lying, sitting or standing position” [8,9] was used to
determine a fall. For this analysis, participants were clas-
sified as fallers if they had fallen to the ground at least
twice during the same 12-month period.
Exposure variables
The Structured Clinical Interview for Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition,
Non-patient edition (SCID-I/NP) was used to assess life-
time history of depressive disorders, including major
depressive disorder (MDD), minor depression, bipolar
disorder, dysthymia, mood disorder due to a general
medical condition, and substance induced mood disorder
and anxiety disorders, including panic disorder, agorapho-
bia, social phobia, specific phobia, obsessive-compulsive
disorder, generalised anxiety disorder, anxiety disorders
due to a general medical condition, substance induced
anxiety disorder and anxiety disorders not otherwise
specified [10]. Participants were classified as having
12-month, past (prior to 12-month), or no history of
depressive or anxiety disorders. Trained personnel, with
qualifications in psychology, conducted all psychiatric
interviews.
Antidepressant and benzodiazepine use was self-
reported and was deemed current if used regularly at the
time of assessment. Participants were asked to bring in a
list of medications or containers to assist with accurate
recording of details.
Weight was measured to the nearest 0.1 kg. Informa-
tion on lifestyle and other health factors was obtained
via questionnaire. Mobility was classified as active if
vigorous or light exercise was performed regularly,
sedentary if normal day to day living is achieved but no
appreciable exercise, and limited if activity was restricted
to the point of little walking outside of the home, sits in
chair or lies in bed most of the time, or bedridden. Use
of a walking aid was determined by the question “Do
you use a walking aid” (Yes/No). Current health status
was measured using a self-report 5-point Likert self-
report scale ranging from 1 (Excellent) to 5 (Poor). Alco-
hol and calcium intake was estimated from a validated
food frequency questionnaire [11] and current smoking
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was documented. Socio-economic status (SES) was
ascertained using Socio-Economic Index For Areas
(SEIFA) index scores, based on the 2006 Australian Bur-
eau of Statistics Census data; SEIFA scores were used to
determine the level of SES via the Index of Relative
Socio-economic Advantage and Disadvantage (IRSAD).
The IRSAD accounts for parameters measured at the
area-level, including high and low income, and type of
occupation. A low score using the IRSAD identifies the
most disadvantaged (quintile 1), while a high score iden-
tifies the most advantaged (quintile 5) [12]. Blood pres-
sure was measured (seated) with a digital meter (A&D
Company, model UA-751).
Statistics
Differences in characteristics between those with 12
month, past or no history of depression or anxiety were
determined using analysis of variance (ANOVA), with
Tukey’s Test Statistic for multiple comparisons applied, for
continuous variables, Kruskal-Wallis for non-parametric
continuous variables, and the chi square test for discrete
variables. Post hoc analyses were conducted where ap-
propriate. Logistic regression was used to calculate odds
ratios (OR) with 95% confidence interval (95% CI) for
falls for those with 12-month and past depression in
comparison to those with no depression. The relation-
ship between falls and anxiety disorders (12-month/
past/never), were similarly investigated. Covariates in-
cluded age, weight, psychotropic medication, smoking
status, blood pressure, mobility, use of a walking aid,
health status, SES, alcohol consumption and calcium in-
take. These were tested sequentially and only included
in the final model if significant. In addition to these co-
variates, depressive and anxiety disorders were tested
when exploring the association between falls and use of
any psychotropic medication, antidepressants and benzo-
diazepines. All interactions were tested. Statistical analyses
were performed using Minitab (Version 16; Minitab, State
College Pa) and SPSS statistical package 22.0 for Windows
(SPSS Inc., Chicago, IL, USA).
Results
Depressive disorders and falls
One hundred and forty six (13.8%) women were classi-
fied as having 12-month depression, 148 (13.9%) women
had past depression, and 768 (72.3%) had no history of
depression. The groups differed in age, weight, smoking
status, diastolic blood pressure, walking aid use, health
status, falls history and psychotropic use; otherwise the
groups were similar (Table 1). Those meeting criteria for
12-month depression had a 2.4-fold increased odds of
falling compared to those with no history of depression
(unadjusted OR = 2.4, 95% CI 1.2-4.5, p = 0.01). Adjustmentfor age and mobility strengthened the relationship
(adjusted OR = 2.7, 95% CI 1.4-5.2, p = 0.004) between
depression and falling, with results remaining un-
changed following adjustment for psychotropic medica-
tion use (adjusted OR = 2.7, 95% CI 1.3-5.6, p = 0.01).
Further adjustment for weight, use of walking aid,
smoking status, health status, anxiety disorders, blood
pressure, SES, alcohol consumption or calcium intake did
not affect the association. The odds of falling were not in-
creased among those with past depression (p = 0.35).
Anxiety disorders and falls
Ninety-nine (9.3%) women were classified as having a
12-month anxiety disorder, a further 40 (3.8%) had suf-
fered from an anxiety disorder in the past, and 923
(86.9%) had no previous history. The groups differed in
terms of age, health status and psychotropic medication
use; otherwise the groups were similar (Table 1). Both
12-month (p = 0.06) and past (p = 0.14) anxiety disorders
were not associated with an increased risk of falling.
Psychotropic medication use and falls
One hundred and fifty nine (15.0%) women reported
psychotropic medication use, with 64 (6.0%) reporting
benzodiazepine use and 120 (11.3%) antidepressant use.
Any psychotropic medication use (unadjusted OR = 2.9,
95% CI 1.6-5.2, p ≤ 0.001), antidepressant use (unadjusted
OR= 2.5, 95% CI 1.3-4.9, p = 0.005), and benzodiazepine
use (unadjusted OR = 3.3, 95% CI 1.5-7.1, p = 0.002) were
each associated with falling. Adjustment for age, weight,
mobility, use of walking aid, smoking status, health status,
depressive and anxiety disorders, blood pressure, SES,
alcohol consumption or calcium intake did not explain
the relationships.
Discussion
The findings of this cross-sectional, population-based
study across the adult age spectrum showed that women
meeting criteria for 12-month depression had an in-
creased risk of falling compared to those with no history
of depression independent of anthropometric, demo-
graphic, medical and lifestyle factors. Psychotropic use
was also confirmed as an independent risk factor for
falls; but, interestingly neither past depression nor anx-
iety disorders were associated with falling.
These findings are concordant with recent meta-
analyses of prospective studies reporting depression to
be independently associated with increased odds of re-
current falls in older people [1,3]. Studies investigating
this relationship in samples of community-dwelling and
institutionalised older people have repeatedly reported
positive findings. Within a population-based sample of
7,414 elderly women, depressive symptomatology was
associated with up to a 40% increased odds of falling,
Table 1 Characteristics for the whole group, women with 12-month, past and no past depressive or anxiety disorder
Depressive disorders Anxiety disorders
All 12 month
depression
Past
depression
Never p 12 month
anxiety
Past
anxiety
Never p
n = 146 n = 148 n = 768 n = 99 n = 40 n = 923
Age (yr) 50.0 (33.5-65.0) 47.0 (33.8-59.0)a 46.5 (29.0-59.8)a 52.0 (35.0-68.0) <0.001 44.0 (29.0-56.0)b 54.0 (32.8-64.8) 51.0 (34.0-67.0) 0.008
Weight (kg) 69.4 (61.4-80.8) 72.9 (63.4-82.5)a 71.7 (62.8-79.9) 68.3 (60.9-80.3) 0.03 72.0 (63.4-80.5) 68.7 (60.4-80.2) 69.0 (61.2-81.0) 0.40
Smoking (current) 149 (14.0%) 33 (22.6%)a 22 (14.9%) 94 (12.2%) 0.004 21 (21.2%) 6 (15.0%) 122 (13.2%) 0.09
Systolic BP (mmHg) 125.1 ± 17.5 124.2 ± 17.0 123.5 ± 14.7 125.5 ± 18.0 0.41 122.2 ± 17.8 126.7 ± 16.8 125.0 ± 17.4 0.25
Diastolic BP (mmHg) 75.7 ± 11.0 78.0 ± 10.9a 74.9 ± 9.9 75.4 ± 11.1 0.03 76.1 ± 11.5 76.8 ± 10.7 75.6 ± 10.9 0.75
Mobility (current) 0.10 0.36
Active 831 (78.4%) 107 (73.3%) 123 (83.7%) 601 (78.4%) 74 (74.8%) 34 (85.0%) 723 (78.5%)
Sedentary 174 (16.4%) 32 (21.9%) 21 (14.3%) 121 (15.8%) 21 (21.2%) 3 (7.5%) 150 (16.3%)
Limited 55 (5.2%) 7 (5.3%) 3 (2.3%) 45 (5.9%) 4 (4.0%) 3 (7.5%) 48 (5.2%)
Walking aid (current) 58 (5.5%) 5 (3.4%)a 3 (2.0%)a 50 (6.5%) 0.05 5 (5.1%) 1 (2.5%) 52 (5.7%) 0.68
Health status (current) <0.001 0.04
Excellent-Very good 621 (58.6%) 64 (43.8%)a 83 (56.9%) 474 (61.8%) 48 (48.5%) b 20 (50.0%) 553 (60.1%)
Good 322 (30.4%) 52 (35.6%) 50 (34.3%) 220 (28.7%) 36 (36.4%)b 18 (45.0%)b 268 (29.1%)
Fair-Poor 116 (11.0%) 30 (20.6%)a 13 (8.9%) 73 (9.5%) 15 (15.2%) 2 (5.0%)b 99 (10.8%)
Alcohol intake (g/d) 2.9 (0.4-12.1) 3.1 (0.4-14.8) 3.9 (0.5-14.7) 2.6 (0.3-10.6) 0.06 2.5 (0.3-13.5) 4.7 (0.4-12.4) 2.8 (0.4-11.7) 0.99
Calcium intake (mg/d) 836.9(607.6-1070.2) 836.1(556.6-1098.5) 794.2(572.6-1045.3) 840.6(617.6-1072.0) 0.43 787.8(549.2-1099.4) 920.1(676.2-1208.9) 836.3(608.1-1065.2) 0.32
Falls (2 or more) 56 (5.3%) 14 (9.6%)a 9 (6.1%) 33 (4.3%) 0.03 9 (9.1%) 4 (10.0%) 43 (4.7%) 0.07
Socioeconomic status 0.70 0.89
Quintile 1 (most disadvantaged) 165 (15.4%) 28 (19.2%) 22 (14.9%) 115 (15.0%) 17 (17.2%) 7 (17.5%) 141 (15.3%)
Quintile 2 229 (21.6%) 32 (21.9%) 30 (20.3%) 167 (21.7%) 23 (23.2%) 6 (15.0%) 200 (21.7%)
Quintile 3 242 (22.8%) 32 (21.9%) 34 (23.0%) 176 (22.9%) 19 (19.2%) 11 (27.5%) 212 (23.0%)
Quintile 4 210 (19.8%) 31 (21.2%) 25 (16.9%) 154 (20.1%) 22 (22.2%) 6 (15.0%) 182 (19.7%)
Quintile 5 216 (20.3%) 23 (15.8%) 37 (25.0%) 156 (20.3%) 18 (18.2%) 10 (25.0%) 188 (20.4%)
Psychotropic use (current) 159 (15.0%) 59 (40.4%)a 33 (23.3%)a 67 (8.7%) <0.001 29 (29.3%)b 16 (40.0%)b 114 (12.4%) <0.001
benzodiazepine use 64 (6.0%) 16 (11.0%)a 9 (6.1%) 39 (5.1%) 0.02 13 (13.1%)b 5 (12.5%)b 46 (5.0%) 0.001
antidepressant use 120 (11.3%) 54 (37.0%)a 27 (18.2%)a 39 (5.1%) <0.001 23 (23.2%)b 15 (37.5%)b 82 (8.9%) <0.001
asignificantly different from no lifetime history of depressive disorders (never).
bsignificantly different from no lifetime history of anxiety disorders (never).
Values are given as mean (± SD), median (IQR) or n (%).
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characteristics, medical conditions, functional status,
medication use and other lifestyle factors [13]. Similarly,
depressive symptoms, as measured with a 4-item Geriat-
ric Depression Scale, were shown to be associated with
recurrent falls in a large group of community dwelling
elderly [14]. Utilising a random sample of Medicare
claimants (n = 601,922) from Australia, the odds of a
fall- related injury was found to be approximately two
times greater for elderly men and women with depres-
sion [15]. In a prospective cohort study of community-
dwelling older people examining predictors of recurrent
falls, depression was considered to be as strong a pre-
dictor as abnormal postural sway, two or more falls in
the previous year, and low scores for hand grip strength
[16]. While increased worry and fear of falling in older
people has been repeatedly shown [4], the relationship
between anxiety disorders and falls is less explored. In
contrast to our findings, Whitney et al. found anxiety as
measured by the Goldberg Anxiety Scale to be a signifi-
cant predictor of falling as was poor attention and orien-
tation, increased postural sway with eyes closed, and
antidepressant use in a group of cognitively impaired
older adults [17]. Another study found the prevalence of
anxiety (and depression) to be higher among fallers [18].
These data are consistent with previous findings that
psychotropic medication is associated with falls [5]. A
recent meta-analysis of 71 studies containing data on
risk factors associated with psychotropic drug use
among the elderly reported the pooled OR for the asso-
ciation between falls and any psychotropic use to be 1.78
(95% CI 1.57-2.01) [5]. An earlier meta-analysis of stud-
ies conducted between 1966 and 1996 reported a similar
pooled OR of 1.73 (95% CI, 1.52-1.97) [19]. Both anti-
depressants and benzodiazepine use alone have been
associated with increased falling in the elderly. In the
recent aforementioned meta-analysis, antidepressant
and benzodiazepine use was associated with a 1.66
(95% CI, 1.4-1.95) and 1.48 (95% CI, 1.23-1.77) fold
increased risk of falls, respectively [5]. Dose response
relationships are evident, whereby falls rates among
nursing home residents have been shown to increase
with increasing daily doses of antidepressants [20,21]
and benzodiazepines with greater half-lives [22]. Exam-
ining the time course of falls to identify specific at-risk
periods during antidepressant treatment, Joo et al. [23]
found of the 104 elderly participants, 40 (38%) fell dur-
ing the 21 weeks of treatment, with about half (53%)
falling during the first six weeks, indicating falls moni-
toring is warranted during the acute stages of treat-
ment. Similarly, when comparing new and repeat use
of benzodiazepines, Maxwell et al. [24] reported an
increased risk of fall-related hospitalisation for new
users of benzodiazepines (OR 2.8, 95% CI 2.2-3.6) andtranquillisers (OR 2.0, 95% CI 1.5-2.6), with risk esti-
mates reducing slightly for repeat users. Other psycho-
tropic agents, including sedatives and hypnotics and
antipsychotics, have also been associated with in-
creased falls risk among the elderly [25,26].
Potential mechanistic factors used to explain the rela-
tionship between falls and psychiatric disorders include
perturbations in gait, functional mobility, cognitive im-
pairment, psychomotor retardation, changes in blood
pressure and effects of psychotropic medication [4].
However, in the present study involving individuals
spanning the entire adult age range, psychotropic use,
mobility, and blood pressure did not significantly influ-
ence the relationship between depression and falls. In
general, depression has been shown to be associated
with changes in gait, including decreases in walking
speed, gait unsteadiness, and inability to maintain a
stable walking pattern among the elderly [27-29]. In a
study of 50 older patients diagnosed with either MDD or
bipolar disorder, walking pace tended to be reduced and
gait unsteadiness and swing time variability was in-
creased; this predisposes individuals to falls [30].
Postural instability may also play a role in the risk of
falls. Within a group of 69 patients admitted to a geriat-
ric hospital unit for ‘spontaneous’ unexplained falls dur-
ing a 12-month period, impairment in postural abilities
in the standing position was shown to differ between the
depressed fallers group and non-depressed fallers group
[31]. The antidepressants paroxetine and sertraline have
been associated with increased falls risk among older
adults due to impairments in balance control and body
sway [32,33], although another study in older adults
found no acute changes in body sway after six weeks of
treatment with sertraline [34]. It is noteworthy that the
possible risk imposed by gait changes appears to be a
state rather than a trait marker of depression, as those
with prior but not 12-month depression showed no in-
crease in falls risk.
A major strength of this study is that it examined the
relationship between psychiatric disorders and falls
within a population-based sample spanning the entire
adult age range. Previous research has been limited to
the elderly, with the majority of studies involving sam-
ples of institutionalised participants. In our models,
there was no age interaction, indicating the relationship
between depression and falls was similar for young and
older women. We recognise that this study has some
limitations. Power limitations prevented exploration of
the relationship between specific classes of benzodia-
zepines and antidepressants and falls. Furthermore, we
excluded users of other psychotropic agents, including
sedatives, hypnotics and antipsychotics, due to the
sample size preventing additional subgroup analyses.
Medication dose, duration of therapy, and stability are
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these variables could not be tested in our multivariate ana-
lyses. Likewise, rigorous measures of gait and balance were
also not available to be tested. Last, as in all observational
studies, there may have been unrecognised confounding.
Conclusion
In conclusion, there was an increased likelihood of falls
among those with 12-month depression, independent of
psychotropic medication use and other recognised con-
founders, suggesting an independent association be-
tween depression and falls. Psychotropic use was also
confirmed as an independent risk factor for falls, but
anxiety disorders were not. The poorer health status
observed among women with depression in this study
emphasises the disabilities potentially associated with
this disorder. Together with data suggesting that one in
three community-dwelling individuals over 65 years of
age fall each year [35], alongside the high prevalence of
depression [7,36], both depression and psychotropic use as
risk factors for falls needs to be taken into consideration.
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